Healthcare / Medical DevicesBSE
$119.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-4.8M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.6B
P/E
23.8x
↑EV/EBITDA
N/A
•ROE
34.6%
↑Gross Margin
40.6%
↓Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+22.1%
FCF CAGR
—
FCF margin
0.4%
FCF / Net income
0.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $431.1M · net income $68.8M · FCF $1.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $431.1M | $431.1M | $317.5M | $289.2M |
| Net Income | $68.8M | $68.8M | $30.6M | $13.1M |
| EBITDA | $98.3M | $98.3M | $36.1M | $16.2M |
| EPS | — | — | 2.22 | 0.95 |
| Gross Margin | 40.6% | 40.6% | 32.7% | 28.9% |
| Operating Margin | 21.7% | 21.7% | 10.7% | 5.1% |
| Net Margin | 16.0% | 16.0% | 9.6% | 4.5% |
| Balance Sheet | ||||
| Debt/Equity | 0.25 | 0.25 | 0.31 | 0.19 |
| Current Ratio | 12.67 | 12.67 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $1.8M | $1.8M | $-19.9M | $-4.8M |
| Returns | ||||
| ROE | 34.6% | 34.6% | 23.5% | 20.0% |
| Valuation | ||||
| P/E | 23.75 | 23.75 | — | — |
| Growth & Yield | ||||
| Revenue Growth | 35.7% | 35.7% | 9.8% | — |
| EPS Growth | — | — | 133.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-1.7%
Start / end P/E
n/dx → n/dx
EPS bridge
2.22 → n/d
Residual
-1.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.